drugset / Trial / NCT05107934
Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis
Phase 2/3
Suspended
80 enrolled
R-Pharm Overseas, Inc.
Data Management 365 · collabKeystat, LLC · collab
RandomizedSequentialDouble-blindTreatment
Summary
The primary purpose of this study is the evaluation of the efficacy and safety of RPH-104 treatment in patients with recurrent pericarditis. Pharmacokinetic and pharmacodynamic parameters of RPH-104 multiple doses in this patient population will be assessed as well.
Timeline
- Start
- 2025-12
- Primary completion
- 2027-05
- Completion
- 2027-10
Outcome
Outcome not reported
Stopped (Enrollment): “due to the decision of company Top management. No subjects were recruited, none of sites were initiated”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Goflikicept | Monoclonal antibody | 80 mg | Subcutaneous |